This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by DeNardo, G. L. Articles by Mills, S. L. Search for Related Content PubMed PubMed Citation Articles by DeNardo, G. L. Articles by Mills, S. L.

Fractionated Radioimmunotherapy of B-Cell Malignancies with ¹³¹I-Lym-1¹

Departments of Internal Medicine, Pathology, and Radiology, University of California, Davis Medical Center, Sacramento, California 95817

Eighteen patients with Stage 4 B-cell malignancies, which were primarily of intermediate or high grade and progressive despite multiple drug chemotherapy and external irradiation, were treated with fractionated doses of ¹³¹I-labeled Lym-1. Lym-1 is an IgG2a monoclonal antibody that was produced by immunizing mice with Raji cell nuclei that originated from a patient with African Burkitt's lymphoma. Despite advanced disease, 10 of the patients had objective evidence for a complete or partial remission. Toxicity was very modest except in one patient who developed hypotension. Dose-dependent hepatic uptake of Lym-1 was observed in the patients and in BALB/c mice suggesting receptor-mediated recognition of this murine antibody.